頁籤選單縮合
題名 | Pioglitazone Monotherapy Improves Daily Plasma Glucose and Insulin Concentrations in Type 2 Diabetic Subjects: A Double-Blind, Placebo-Controlled Trial=Pioglitazone單一藥物可改善第二型糖尿病整日血糖及胰島素濃度:雙盲、安慰劑對照組試驗 |
---|---|
作者姓名(中文) | 洪乙仁; 裴馰; 郭熙文; 謝昌勳; 何志聰; 沈德昌; 許惠恆; | 書刊名 | Journal of Medical Sciences |
卷期 | 26:1 民95.02 |
頁次 | 頁19-24 |
分類號 | 418.271 |
關鍵詞 | 糖尿病; 血糖; 胰島素; Insulin sensitivity; Pioglitazone; Postprandial metabolism; |
語文 | 英文(English) |
英文摘要 | Background: The aim of this study was to evaluate the efficacy of pioglitazone (PIO) on insulin sensitivity and postprandial metabolism in patients with type 2 diabetes who were on diet control alone. Methods: This study is a randomized, double-blind, parallel comparison study, comparing PIO 30 mg/day and placebo. A total of 27 type 2 diabetic patients (age 53.37±0.71 years and BMI 25.77±1.78 kg/m²) who controlled their diabetes with diet alone, were randomly assigned to receive either placebo (n=14) or PIO (30 mg/day) (n=13) for 12 weeks. Before and after 12 weeks of treatment, all subjects received a modified insulin supression test for quantitatively defining insulin sensitivity and a mixed meal tolerance test for determinations of ambient glucose, insulin and triglyceride. Results: After 12 weeks of PIO treatment, PIO resulted in a significant reduction of fasting plasma glucose (FPG) (11.03±1.11 vs 9.53±1.36 mmol/L, P<0.005), fasting plasma insulin (FPI) (197.16±22.06 vs 155.78±14.29 pmol/L, P<0.05) and HbA1c (9.20±0.36 vs 8.25±0.44%, P<0.005). There was no significantly effect of PIO treatment on fasting lipid profile. The steady-state plasma glucose (SSPG) level was also significantly decreased (18.64±1.54 vs 15.67±1.66 mmol/L, P<0.05) with similar steady-state plasma insulin (SSPI) concentration. Both postprandial plasma glucose and insulin levels were ameliorated (P<0.05) without a significant effect on postprandial triglyceride concentration. Conclusions: PIO not only improves fasting glycemic index and insulin sensitivity, but also has a marked benefit on postprandial glycemic control, with a reduction of postprandial insulin levels. However, PIO could not improve postprandial triglyceride concentrations in type 2 diabetic patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。